<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types
Background Image

4D-DIA Quantitative Proteomics

State-of-the-art Combination of 4D Proteomics and DIA Technology

Entering New Era of Mass Spectrometry-based Proteomics

A new generation of 4D-DIA proteomics technology combines 4D proteomics, which added ion mobility as the fourth separation dimension to traditional LC-MS/MS (retention time, m/z and MS/MS fingerprint), with data independent acquisition (DIA) strategy, which avoids data imbalance caused by randomness by realizing "lossless acquisition" of all possible data.

4D-DIA Proteomics

 

What is 4D Proteomics?

Classic LC-MS/MS-based bottom-up proteomics separate peptides based on three dimensions:  chromatographic retention time (RT); mass-to-charge ratio (m/z) and ion intensity.

Ion mobility analysis is a gas-phase technique allowing the separation of ions based on their mobility through an inert gas (typically helium or nitrogen) under the influence of an electric field. Adding ion mobility as an additional dimension of separation for peptide ions to LC-MS/MS analysis make MS-based proteomics enter a new era. 

It significantly improves the scanning speed and detection sensitivity, as well as enhances proteomic analysis performance in terms of identification depth, detection cycle, and quantitative accuracy.

image-png-Dec-07-2022-05-04-59-7057-AM

Data Dependent/Independent Acquisition (DDA/DIA)

There are two data acquisition strategies in tandem mass spectrometry (MS/MS) data acquisition:


DDA mode:
The mass spectrometer selects a fixed number of most intense precursor ions. They are then fragmented and analyzed, in the second stage of tandem mass spectrometry.

DIA mode: The mass spectrometer divides the full scan range of mass spectrometry into several windows and selects, fragments, and collects all ions in each window.


DIA strategy avoids data imbalance caused by randomness by realizing "lossless acquisition" of all possible data. However, the "all-acquisition" strategy produces a highly complex spectrogram that poses a great challenge to data analysis. 
 

image-png-Dec-07-2022-05-08-09-7422-AM

 


Technical Strengths of 4D-DIA Quantitative Proteomics

Improved Detection Accuracy and Reliability

 

The greatest challenge in traditional DIA without ion mobility separation lies in the difficulty of reliably analyzing mixed spectra. During quantification, matching is mainly based on chromatographic elution time (retention time). However, due to co-elution, the retention time alone is not enough, and many other interfering signals will affect the detection accuracy.

4D technology provides ion-mobility separation and adds an extra dimension for calibration. It can accurately discriminate the specific peptide signals from the mixed spectra of DIA, effectively reducing spectra complexity and improving the detection accuracy and reliability of DIA.

Fig. The chromatograms of EVGSHFDDFVTNLIEK peptide after calibration in traditional DIA (left) and 4D-DIA (right). There is a high interference signal in the traditional DIA method (left), while the signal background in the 4D-DIA (right) is very clean.

 

Nearly 100% Ion Utilization, Maximized Detection Sensitivity

 

In the 4D-diaPASEF scanning mode, the ion-mobility-related CCS value correlates well with m/z. This feature allows the Quadrupole to scan gradually to collect nearly 100% of the ion signals, greatly enhancing the sensitivity and depth of detection.

In comparison, in the traditional LC-MS/MS-based proteomics without ion mobility separation, only limited signals can be collected.

image-png-Dec-07-2022-05-15-10-5648-AM

Fig. 4D-DIA based on the 4D platform can reach nearly 100% ion utilization. Left, Data acquisition in 4D-DIA mode; Right, Comparison of ion utilization among 4D-DIA, DDA, and DIA. (Source: Florian Meier, et al. Nature Methods.)

Significant Improvement in Detection Depth

 

4D-DIA identifies and quantifies low-abundant proteins more accurately than traditional methods, thereby increasing the depth of proteomics detection.

image-png-Dec-07-2022-05-16-01-3167-AM

Fig. >7,500 proteins can be identified from a single injection of 200 ng of HeLa lysate (120-minute run time), and 6,974 proteins can be quantified with 96% data completeness in triplicate runs. In comparison, conventional proteomics usually requires μg-level samples to detect about 5,000 proteins.

 

Better quantitative integrity

 

4D-DIA technology can further push the limits of sensitivity with advanced instrument performance and upgraded acquisition methods. Even at this trace level, 4D-DIA showed 85% data integrity for protein quantification.

image-png-Dec-07-2022-05-17-00-1037-AM

Fig. >3,000 protein can be identified from a single injection of 10 ng HeLa lysate (120-minute run time), and 3,323 proteins can be identified by triplicated runs. While under the same study conditions, the 4D-DDA mode could only identify 2,723 proteins.

Request a quote